IMU

2.04%

5.0¢

IMUGENE LIMITED

Market Cap $371.8M Add to my watchlist

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Latest Threads

Tag

Subject

IMU

Why IMU is a multi multi bagger

444 445 446

09:29

26K

13M

09:29

Last post mrdingo

26K

13M

IMU Biotech

IMUGENE CHART. TA only

578 579 580

08:55

34K

17M

08:55

Last post

slick

34K

17M

IMU

Ann: Imugene Receives Orphan Drug Designation for VAXINIA

5 6 7

07:27

369

131K

07:27

Last post Mason14

369

131K

IMU

Media Thread

259 260 261

07:04

15K

7.4M

07:04

Last post Bluegumnuts

15K

7.4M

IMU

Shareholders to be answered at AGM !

2 3

25/09/24

170

57K

25/09/24

Last post Dhm

170

57K

IMU

Ann: Imugene Webinar - Azer-cel Trial Update

2 3 4

24/09/24

189

83K

24/09/24

Last post mumstheword

189

83K

IMU

Rubbing my ball

28 29 30

20/09/24

1.7K

1.0M

20/09/24

Last post bavarian1975

1.7K

1.0M

IMU

FDA orphan designation

19/09/24

18K

19/09/24

Last post Bluegumnuts

18K

See All Discussions

Timeline

Imugene Receives Orphan Drug Designation for VAXINIA
18 Sep 13:06	Share

Appendix 2A
11 Sep 16:59	Share

Imugene Corporate Presentation
09 Sep 10:12	Share

Cleansing Notice
04 Sep 16:32	Share

Application for quotation of securities - IMU
04 Sep 16:29	Share

Imugene Azer-cel Webinar Presentation
04 Sep 10:19	Share

Imugene Webinar - Azer-cel Trial Update
03 Sep 08:26	Share

Three Complete Responses in Azer-Cel Phase 1b Trial
02 Sep 08:44	Share

Imugene ESG Report 2024
30 Aug 18:44	Share

Corporate Governance Statement 2024 and Appendix 4G
30 Aug 18:43	Share

Appendix 4E and Annual Report
30 Aug 18:43	Share

Release of Shares from Voluntary Escrow
02 Aug 17:59	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jul 09:16	Share

Notification of cessation of securities - IMU
12 Jul 17:28	Share

Notification regarding unquoted securities - IMU
12 Jul 17:19	Share

First patient dosed in Phase 1 bile tract cancer trial
10 Jul 09:20	Share

Change of Director's Interest Notice x6
08 Jul 16:50	Share

Application for quotation of securities - IMU
08 Jul 11:20	Share

Imugene Corporate Presentation
04 Jul 15:44	Share

Imugene onCARlytics Doses First Patient in IV Combination
24 Jun 08:24	Share

Imugene Presentation to Bell Potter Conference
30 May 12:06	Share

Application for quotation of securities - IMU
06 May 16:10	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 08:48	Share

Change of Director's Interest Notice - PH
23 Apr 16:50	Share

Notification regarding unquoted securities - IMU
19 Apr 16:27	Share

Imugene & Kincell Bio Strategic Partnership Investor Webinar
17 Apr 10:31	Share

Imugene and Kincell Bio Announce Strategic Partnership
16 Apr 08:34	Share

Notification of cessation of securities - IMU
15 Apr 18:27	Share

Notification regarding unquoted securities - IMU
15 Apr 18:25	Share

Bile Tract Cancer Study Opens after MAST High Dose Clearance
15 Apr 08:36	Share

View More

(20min delay)
Last 5.0¢		Change 0.001(2.04%)		Mkt cap ! $371.8M

Open	High	Low	Value	Volume
4.9¢	5.1¢	4.9¢	$776.4K	15.58M

Buyers (Bids)

No.	Vol.	Price($)
37	6526158	4.9¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	1499998	1

View Market Depth

No.	Vol.	Price($)
3	75637	0.050
33	4288605	0.049
51	9701143	0.048
34	3594597	0.047
25	1920916	0.046

Price($)	Vol.	No.
0.049	21500	1
0.050	122387	2
0.051	7002699	12
0.052	2543350	7
0.053	896882	8

Last trade - 16.10pm 26/09/2024 (20 minute delay)


Last 5.0¢		Change 0.001 ( 1.01 %)
Open	High	Low	Volume
4.9¢	5.1¢	4.9¢	8867527
Last updated 15.59pm 26/09/2024 ?

IMU (ASX) Chart

IMUGENE LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Imugene (ASX:IMU) doses first patients in VAXINIA combination study

03 Mar 2023 14:39 (AEDT)

Imugene (ASX:IMU) receives US patent for PD1-Vaxx

10 Feb 2023 10:58 (AEDT)

Imugene (ASX:IMU) advances VAXINIA trial

02 Feb 2023 12:21 (AEDT)

Latest Articles

Imugene's azer-cel trial sees tumours temporarily disappear in 3 of 10 patients

Imugene (ASX:IMU) has announced 3 patients in its latest blood cancer treatment trial using azer-cel have responded well with one showing a complete response for over 100 days. A @complete response’ in this case is a complete disappearance of all tumours. The company is focusing o...

Imugene doses first cancer patient in Oasis trial

Imugene Limited (ASX: IMU), has dosed the first patient in the phase 1 clinical trial known as OASIS, which is testing its oncolytic virotherapy drug.The clinical trial is targeting adult patients with advanced or metastatic solid tumours. The primary objective of the trial is to evaluate the saf...

Imugene expands study for bile tract cancer patients

Imugene will be expanding its trial to treat gastrointestinal cancers - including bile tract cancer - and is enrolling ten more patients for this purpose.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News